John A Hovanesian1, John D Sheppard1, William B Trattler1, Johnny L Gayton1, Ranjan P Malhotra1, David T Schaaf2, Edmund Ng1, Steven H Dunn1. 1. From Harvard Eye Associates (Hovanesian), Orange County, California, Virginia Eye Consultants (Sheppard), Norfolk, Virginia, Center for Excellence in Eye Care (Trattler), Miami, Florida, Eyesight Associates, Warner Robins and Mercer Medical School (Gayton), Macon, Georgia, Ophthalmology Associates (Malhotra), St. Louis, Missouri, Omeros Corporation (Schaaf), Seattle, and Pacific Northwest Statistical Consulting (Ng), Woodinville, Washington, and Houston Eye Associates (Dunn), Houston, Texas, USA. 2. From Harvard Eye Associates (Hovanesian), Orange County, California, Virginia Eye Consultants (Sheppard), Norfolk, Virginia, Center for Excellence in Eye Care (Trattler), Miami, Florida, Eyesight Associates, Warner Robins and Mercer Medical School (Gayton), Macon, Georgia, Ophthalmology Associates (Malhotra), St. Louis, Missouri, Omeros Corporation (Schaaf), Seattle, and Pacific Northwest Statistical Consulting (Ng), Woodinville, Washington, and Houston Eye Associates (Dunn), Houston, Texas, USA. Electronic address: dschaaf@omeros.com.
Abstract
PURPOSE: To evaluate the efficacy and safety of phenylephrine 1.0%-ketorolac 0.3% (Omidria) for maintenance of mydriasis during, and reduction of ocular pain after, cataract surgery. SETTING:Twenty centers in the United States and the Netherlands. DESIGN: Prospective randomized clinical trials. METHODS:Patients having cataract surgery or refractive lens exchange were enrolled in 2 clinical trials. Phenylephrine 1.0%-ketorolac 0.3% or placebo was added to irrigation solution and administered intracamerally during the procedure. Integrated analyses of primary and secondary endpoints were conducted. RESULTS: The clinical trials comprised 808 patients (403 treatment and 405 placebo). Phenylephrine 1.0%-ketorolac 0.3% was superior to placebo for the maintenance of mydriasis during, and reduction of ocular pain following, cataract surgery. The mean area under the curve (AUC) change from baseline in pupil diameter was 0.08 mm for treatment compared with -0.50 mm for placebo (P < .0001). The mean AUC of ocular pain visual analog scale scores within 12 hours postoperatively was 4.16 mm for the treatment group and 9.06 mm for the placebo group (P < .001). Results of all secondary efficacy analyses demonstrated a significant treatment effect associated with phenylephrine 1.0%-ketorolac 0.3%. Treatment-emergent adverse events were as expected for a population having cataract surgery; no clinically significant differences in safety measures were observed between treatment groups. CONCLUSION: In this integrated analysis, phenylephrine 1.0%-ketorolac 0.3% administered intracamerally with irrigation solution during cataract surgery was safe and effective for maintaining mydriasis during the procedure and reducing postoperative ocular pain. FINANCIAL DISCLOSURE: Dr. Schaaf is an employee and holds an equity interest in Omeros Corporation. Drs. Hovanesian, Sheppard, Trattler, Gayton, and Ng are consultants to Omeros Corporation. No other author has a financial or proprietary interest in any material or method mentioned.
RCT Entities:
PURPOSE: To evaluate the efficacy and safety of phenylephrine 1.0%-ketorolac 0.3% (Omidria) for maintenance of mydriasis during, and reduction of ocular pain after, cataract surgery. SETTING: Twenty centers in the United States and the Netherlands. DESIGN: Prospective randomized clinical trials. METHODS:Patients having cataract surgery or refractive lens exchange were enrolled in 2 clinical trials. Phenylephrine 1.0%-ketorolac 0.3% or placebo was added to irrigation solution and administered intracamerally during the procedure. Integrated analyses of primary and secondary endpoints were conducted. RESULTS: The clinical trials comprised 808 patients (403 treatment and 405 placebo). Phenylephrine 1.0%-ketorolac 0.3% was superior to placebo for the maintenance of mydriasis during, and reduction of ocular pain following, cataract surgery. The mean area under the curve (AUC) change from baseline in pupil diameter was 0.08 mm for treatment compared with -0.50 mm for placebo (P < .0001). The mean AUC of ocular pain visual analog scale scores within 12 hours postoperatively was 4.16 mm for the treatment group and 9.06 mm for the placebo group (P < .001). Results of all secondary efficacy analyses demonstrated a significant treatment effect associated with phenylephrine 1.0%-ketorolac 0.3%. Treatment-emergent adverse events were as expected for a population having cataract surgery; no clinically significant differences in safety measures were observed between treatment groups. CONCLUSION: In this integrated analysis, phenylephrine 1.0%-ketorolac 0.3% administered intracamerally with irrigation solution during cataract surgery was safe and effective for maintaining mydriasis during the procedure and reducing postoperative ocular pain. FINANCIAL DISCLOSURE: Dr. Schaaf is an employee and holds an equity interest in Omeros Corporation. Drs. Hovanesian, Sheppard, Trattler, Gayton, and Ng are consultants to Omeros Corporation. No other author has a financial or proprietary interest in any material or method mentioned.
Authors: Paolo Nucci; Andrea Lembo; Roberto Caputo; Andrea Dellavalle; Massimiliano Serafino; Irene Schiavetti; Francesco Pichi Journal: Int Ophthalmol Date: 2022-09-02 Impact factor: 2.029
Authors: Rafael B de Araújo; Breno M S Azevedo; Thais S Andrade; Maria F Abalem; Mário L R Monteiro; Pedro C Carricondo Journal: Int J Retina Vitreous Date: 2018-10-17
Authors: Mario D Toro; Dominika Nowakowska; Agnieszka Brzozowska; Michele Reibaldi; Teresio Avitabile; Claudio Bucolo; Paolo Murabito; Clara Chisari; Katarzyna Nowomiejska; Robert Rejdak Journal: Front Pharmacol Date: 2020-04-16 Impact factor: 5.810